Epoxyketone proteasome inhibitors have attracted much interest due to their potentiala sa nticancer drugs. Although the biosynthetic gene clusters for severalp eptidyl epoxyketone natural products have recently been identified, the enzymatic logic involved in the formationo ft he terminal epoxyketone pharmacophore has been relatively unexplored. Here, we report the identification of the minimal set of enzymes from the eponemycin gene clustern ecessary for the biosynthesis of novel metabolites containing at erminal epoxyketone pharmacophore in Escherichia coli,aversatile and fast-growing heterologous host. This set of enzymes includes an on-ribosomal peptides ynthetase (NRPS), ap olyketide synthase (PKS), and an acyl-CoA dehydrogenase (ACAD) homologue.I na ddition to the in vivo functional reconstitution of these enzymes in E. coli, in vitro studies of the eponemycin NRPS and 13 C-labeled precursor feeding experimentsw ere performed to advance the mechanistic understanding of terminal epoxyketone formation.
Peptidyle poxyketones are ac lass of proteasome inhibitors consisting of as hort peptide core and at erminal epoxyketone moiety.O ver the past few decades, av ariety of these natural products,i ncluding eponemycin (1), epoxomicin (2) , and other related compounds, have been isolated from aw ide range of bacterials ources( Scheme 1). [1] [2] [3] [4] More recently,s everal additional epoxyketone proteasome inhibitors, specifically the clarepoxins, landepoxins, and macyranone A, were discovered throughm etagenome mining [5] and NMR screening approaches. [6] Although these naturally-occurring peptidyl epoxyketones exhibit great structurald iversity in the length and composition of their peptidec ore and can also differ in the substitution on the epoxide ring, all of them possess a commont erminal epoxyketone pharmacophore, which is responsible for their high efficacy and specificity as proteasome inhibitors. In particular,t he strongly electrophilicc arbonyl and epoxide groups are highly susceptible to ad ouble nucleophilic attack by the N-terminal threonine of the 20S proteasome, leadingt ot he irreversible formation of am orpholino ring. [7] [8] [9] Consequently,t hese natural products have inspired the current development of anticancer,a nti-inflammatory,a nd antiparasitic drugs with at erminal epoxyketone warhead. [10] [11] [12] One such example is the synthetic epoxomicin analogue,c arfilzomib (Scheme 1), which has been used as at reatment for relapsed and refractory multiple myeloma. [13] [14] Given the potency andu nique structure of these peptidyl epoxyketone natural products, there has been great interest in the biosynthetic origins of these compounds. In particular,t he geneticb asis for the biosynthesis of epoxomicin and eponemycin was recently identified from Goodfellowiella coeruleoviolacea and Streptomyces hygroscopicus,r espectively (Figure 1A) . [15] Moreover, gene clusters responsible for the biosynthesis of clarepoxins and landepoxins were recently identified in soil metagenomic libraries, [5] and the gene cluster responsible for the biosynthesis of macyranones was identifiedi nt he genome of Cystobacter fuscus MCy9118. [6] However,t he specific enzymes and chemicall ogic governingt he formationo ft he terminal epoxyketone pharmacophore have not yet been fully elucidated. Nonetheless, bioinformatics analysish as shown four genes to be conserved across the epoxomicin ande ponemycin gene clusters, and these genes encodeanon-ribosomal peptides ynthetase (NRPS): EpnG/EpxD;apolyketide synthase (PKS): EpnH/EpxE;a na cyl-CoA dehydrogenase (ACAD) homologue:E pnF/EpxF;a nd ac ytochrome P450 monooxygenase: EpnI/EpxC.B ased on this analysis, ab iosynthetic pathway in which ah ybrid NRPS-PKS assembly line generates ac arboxylic acid that is subsequently modified by the ACAD and cytochromeP 450 to form the terminale poxyketone moiety was previously proposed. [15] Notably,h owever,t he recentlyi dentified gene cluster for macyranone biosynthesis lacks ag ene encoding ac ytochrome P450, which led to an alternative acylcarrier-bound proposed mechanismf or epoxyketone formation involving the ACADh omologue,M ynC, and possibly the type II thioesterase, MynH. [6] In this work, we build upon the previous study of the biosynthesis of eponemycin and epoxomicin by turning to reconstitutioni nEscherichiac oli as am eans to quicklya nd systematically identify the enzymes necessary for the generation of the terminale poxyketone moiety.D ue to its genetict ractability, fast growth rate, and well-characterized metabolism, E. coli is ap articularly attractive host for studying the biosynthesis of natural products. [16] [17] [18] [19] Furthermore, the reconstitution of NRPS-PKS activityi nE. coli provides as uperior platform for the overproduction and diversification of their products. [20] [21] To determine the enzymes required for the biosynthesis of the terminal epoxyketonep harmacophore, we co-expressed the four genes from the eponemycin gene cluster (epnFGHI)p ro-posed to be involved in E. coli on three plasmids. The plasmids were co-transformed into E. coli BAP1, which contains ac hromosomalc opy of the phosphopantetheinyl transferase encoding gene, sfp, [22] to generatet he strain JL6. An egative control strain transformed with empty vectors was also constructed. Although the natural fatty acyl moietyi ne ponemycin is derived from 6-methyl heptanoic acid, which is uncommon in bacterialp rimary metabolism [23] and is presumably generated by dedicated enzymes encoded in the eponemycin biosynthetic gene cluster, [15] we reasoned that EpnG-activated serine could possibly be condensed with hexanoyl-or octanoyl-CoA produced endogenously by E. coli ( Figure 1A) . Consequently, cultures of JL6 weres upplemented with 1mm hexanoic acid or octanoic acid at the time of inductiont op romote the incorporation of these alternative fatty acyl groups into the assembly line. The culture extracts of JL6 and the controls train were analyzed by liquid chromatography-highr esolution mass spectrometry( LC-HRMS)-based comparativem etabolomics, [24] and two new compounds (3 and 4)w ith masses consistent with molecular formulaeo fC 18 H 32 N 2 O 5 and C 20 H 36 N 2 O 5 ,r espectively, were detected in high abundance in the extracts of JL6 but were absent from the extracts of the control strain (Figures 1B and S1-2). Further HRMS/MS analysisc onfirmed 3 and 4 to be consistentw ith aC 6 or C 8 fatty acyl group condensed with serine, leucine, and malonate, but it did not give insight into the structure of the terminal moiety resulting from modifications on the malonate (Figures S1 and S2) .
To reveal the exact molecular structure of the new compounds, we then scaled up the production cultures and purified~2mgo ft he major product, 4,f or NMR spectroscopic analysis. Compound 4 was purified by following the fractions using LC-MSt og ive ay ield of~0.2 mg L
À1
.A nalysis of the 1D ( 1 H, 13 C) and 2D (HSQC, COSY,H MBC) NMRs pectra of purified 4 confirmed the presence of an acylated peptidec omposed of an eight-carbon fatty acyl chain, serine, and leucine connected to am ethyl-substituted epoxyketone ( Figures 1a nd S3-S7 , Ta ble S3). Notably,t he proton and carbon shifts of the methylsubstituted epoxyketone and leucine residue are in strong agreement with those reportedf or as tandard of 2,w hich has these same functionalities. [2] Moreover,t he methyl-substituted quaternary epoxider ing was supported by HMBC correlations from the C3 methyl protons (d H = 1.52) to both the quaternary carbon C2 (d C = 59.5) and the oxygenated methylenec arbon C1 (d C = 52.7) and by HMBCc orrelations from the C1 protons (Figures 1a nd S7 , Ta ble S3). Thus, based on our HRMS and NMR analyses, we determined 4 to be an ew terminal epoxyketonecompound.
To probe the necessity of individual enzymes in the formation of 3 and 4,w es ystematicallyr emovede ach of the four genes from JL6 and compared the product profiles of the resulting strains.A nalysis of the culturee xtracts of these strains by LC-HRMS showedt hat the production of 3 and 4 was abolished in JL7, JL8, and JL9, which lack epnG, epnH,a nd epnF,r espectively,b ut was maintained in JL10, which lacks epnI (Figure 1B) . Moreover,L C-HRMS-based comparative metabolomics did not show any differences between the extracts of JL6 and JL10, and the titers of 3 and 4 were comparable in both strains,c onfirming that EpnI is not necessary for the formation of 4 in E. coli,t hough its function remains unclear.T hese results demonstrate that the NRPS, PKS, and ACAD are sufficient for the biosynthesis of peptidyl epoxyketones in E. coli,and epoxide formation does not necessarily requireacytochrome P450 monooxygenase. This result is also consistentw ith the recent study on macyranone biosynthesis in which the reported gene clusterdid not contain any genes encoding for acytochromeP 450, neither could ac lose homologueo fE pxC/EpnI be identified elsewhere on the C. fuscus MCy9118 genome. [6] In addition, the titers of 3 and 4 from JL11i nw hich epnH is replaced by epxE appeared to be slightly greatert han those from JL10, demonstrating the interchangeability of EpnH and its homologue, EpxE (similarity/identity:5 5%/44 %), which is encoded in the epoxomicin biosynthetic gene cluster. Interestingly,n oa pparent small molecule intermediates could be detected by LC-HRMS-based comparativem etabolomics analysis of the culture extracts of astrain expressing only the NRPS and PKS together,s uggesting that the ACAD might act on the assembly line.
To complement the in vivo studies of EpnF,G ,H ,a nd I, we also attempted to perform in vitro characterization of these enzymes,b eginning with EpnG, the dimodule NRPS that has ad omain organizationo fC 1-A1-T1-C2-A2-T2 (C:c ondensation, A: adenylation, T: thiolation) ( Figure 1A and S8) . The Adomain substrate specificities of EpnG were tested by using the wellestablished ATP-[ 32 P]PP i exchange assay. [25] As expected, EpnG demonstrated as trong preference for l-serinea nd l-leucine, thoughi tw as also able to activate l-cysteine, l-alanine, and l-threonine to some extent ( Figure 1C) . Unfortunately,p urification of the active PKSs EpnH and EpxE from E. coli or Streptomyces hosts was unsuccessful ( Figure S8 ), which prevented further biochemical study of theseenzymes.
To better elucidate the biosynthetic mechanism for terminal epoxyketone formation,wetook advantage of our E. coli heterologous expression system and used it to perform 13 C-labeled precursor feeding studies. Twop ossible mechanisms( pathwaysA and B) for terminale poxyketone formation have been previously proposed (Scheme 2). [15] PathwayA postulates the introduction of as ingle methyl group at C2, followed by the reductionoft he carboxylica cid to an olefin that can then undergo epoxidation,w hereas pathway Bp roposes dimethylation at C2, followed by decarboxylation of the carboxylic acid and subsequente poxide installation. [15] To distinguish between these two possibilities, we fed [1, [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C]sodium acetate to cultures of JL11, the highest producing strain, and compared the www.chembiochem.org resulting 13 Ci ncorporation to that from unlabeled and [1-13 C]sodium acetate feeding (Scheme2 and Figure S9-10) .A lthought he titerso fl abeled 3 and 4 were insufficientf or NMR analysis, LC-HRMS analysis of 3 and 4 from the extracts of cultures fed with [1,2- 13 C]sodium acetate showed as ignificant increase in the ratio of the M+ +1p eak intensity to the M+ + peak intensity compared to that of cultures fed with unlabeled and [1-
13 C]sodium acetate (FiguresS9a nd S10). Further HRMS/MS analyses and examination of the isotope distribution of fragments with and withoutt he epoxyketone group indicated that this increase is the result of as ingle 13 Ca tom from doubly labeled acetate being incorporated as the C2 carbon of 3 and 4 after decarboxylation (Scheme 2a nd Figure S9-10) . To evaluate the occurrence of dimethylation, we then separately fed [methyl- 13 C] L-methioninet oc ultures of JL11, as methionine is the precursor of the predicted methyl group donor, S-adenosylmethionine (SAM). This feeding experiment resulted in as ignificanti ncreasei nt he ratio of the M+ +2p eak to the M+ + peak for both 3 and 4,w hich is indicative of the incorporation of two 13 Ca toms, and additional HRMS/MS analyses showed that these 13 Ca toms were incorporated into the epoxyketone-containing fragment of 3 and 4 (Scheme 2, Figures S9 andS 10) . These feeding results thus support pathway B, in whichC 2i s dimethylated by the C-methyltransferase( cMT) domain of the PKS and, either following or in concert with the activity of the ACAD, decarboxylation of at erminal carboxylic acid takes place.
In summary,w ehave made headway in elucidating the biosynthesis of peptidyl epoxyketones,and in addition to generating new peptidyl epoxyketone products in E. coli,w es ystematically identified the minimal set of enzymes necessary for doing so. Specifically,t hrough our reconstitution of the hybrid NRPS-PKS assembly line in E. coli,w efound that only one additional modification enzyme, an ACAD homologue that presumably functions on the assembly line, is required for terminal epoxyketone formation. Furthermore, 13 C-labeled precursor feeding studies suggest that the formation of the epoxyketone pharmacophore involves ad imethylationa nd as ubsequent decarboxylation reaction. The work reportedh ere demonstratest he first productiono fp eptidyl epoxyketones by E. coli and paves the way forf urther biochemical characterization of the PKS andA CADt ou nderstand their precise roles in forming the potent and unique terminal epoxyketone pharmacophore.
Experimental Section
Full experimental details are available in the Supporting Information.
